

**Choice of Abstracts & Summary of the presentation from Thomas Seufferlein:
Improving the outcome of patients with metastatic pancreatic cancer**

Sunil Hingorani, et al.

[O-003 PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine](#) (password restricted access)

Andrew Hendifar, et al.

[O-028 Tumor Hyaluronan May Predict Benefit From PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma \(mPDA\)](#) (password restricted access)

Thomas Seufferlein, MD

[Improving the outcome of patients with metastatic pancreatic cancer](#) (password restricted access)

Written summary of Thomas Seufferlein's presentation :



[Summary](#)

Late breaking abstract:

T Bekaii-Saab, A Starodub, B El-Rayes, B O'Neil, S Shahda, et al.

[LBA-002 A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine \(gem\) & nab-paclitaxel \(nabptx\) in metastatic pancreatic adenocarcinoma \(mpdac\) patients \(pts\)](#)